Identification

Name
Conivaptan
Accession Number
DB00872  (APRD01302)
Type
Small Molecule
Groups
Approved, Investigational
Description

Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).

Structure
Thumb
Synonyms
  • 4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
  • Conivaptan
External IDs
YM 087 / YM-087
Product Ingredients
IngredientUNIICASInChI Key
Conivaptan hydrochloride75L57R6X36168626-94-6BTYHAFSDANBVMJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vaprisol Dextrose In Plastic ContainerInjection, solution20 mg/100mLIntravenousCumberland Pharmaceuticals2008-10-08Not applicableUs
International/Other Brands
Vaprisol
Categories
UNII
0NJ98Y462X
CAS number
210101-16-9
Weight
Average: 498.5744
Monoisotopic: 498.205576096
Chemical Formula
C32H26N4O2
InChI Key
IKENVDNFQMCRTR-UHFFFAOYSA-N
InChI
InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
IUPAC Name
N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2(6),3,10,12-pentaene-9-carbonyl}phenyl)-2-phenylbenzamide
SMILES
CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1

Pharmacology

Indication

For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.

Structured Indications
Pharmacodynamics

Conivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range by increasing permeability of the renal collecting ducts to water. Vasopressin also causes vasoconstriction through its actions on vascular 1A receptors. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. Conivaptan's antagonist activity on V1A receptors may also cause splanchnic vasodilation, resulting in possible hypotension or variceal bleeding in patients with cirrhosis. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.

Mechanism of action

Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water.

TargetActionsOrganism
AVasopressin V1a receptor
antagonist
Human
AVasopressin V2 receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

99%

Metabolism

CYP3A4 is the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan. Four metabolites have been identified. The pharmacological activity of the metabolites at V1a and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.

Route of elimination
Not Available
Half life

5 hours

Clearance
Not Available
Toxicity

Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Conivaptan can be increased when it is combined with Abemaciclib.Approved, Investigational
AbirateroneThe serum concentration of Conivaptan can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Conivaptan can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Conivaptan can be increased when it is combined with Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Conivaptan can be increased when it is combined with Acetaminophen.Approved
AdinazolamThe serum concentration of Conivaptan can be increased when it is combined with Adinazolam.Approved
AlbendazoleThe serum concentration of Conivaptan can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe serum concentration of Conivaptan can be increased when it is combined with Alclometasone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Aldesleukin.Approved
AlfentanilThe serum concentration of Conivaptan can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Conivaptan can be increased when it is combined with Alfuzosin.Approved, Investigational
AliskirenThe serum concentration of Conivaptan can be increased when it is combined with Aliskiren.Approved, Investigational
AllylestrenolThe serum concentration of Conivaptan can be increased when it is combined with Allylestrenol.Approved
AlmotriptanThe serum concentration of Conivaptan can be increased when it is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Conivaptan can be increased when it is combined with Alogliptin.Approved
AlosetronThe serum concentration of Conivaptan can be increased when it is combined with Alosetron.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of Conivaptan can be increased when it is combined with alpha-Tocopherol acetate.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Conivaptan.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Conivaptan.Illicit
AlprazolamThe serum concentration of Conivaptan can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Conivaptan can be increased when it is combined with Ambrisentan.Approved, Investigational
AmbroxolThe serum concentration of Conivaptan can be increased when it is combined with Ambroxol.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Conivaptan.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Amiloride.Approved
AminophenazoneThe serum concentration of Conivaptan can be increased when it is combined with Aminophenazone.Approved, Withdrawn
AminophyllineThe serum concentration of Conivaptan can be increased when it is combined with Aminophylline.Approved
AmiodaroneThe serum concentration of Conivaptan can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Conivaptan can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Conivaptan can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Conivaptan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Conivaptan.Approved, Investigational
AmprenavirThe serum concentration of Conivaptan can be increased when it is combined with Amprenavir.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Conivaptan is combined with Amyl Nitrite.Approved
AntipyrineThe serum concentration of Conivaptan can be increased when it is combined with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Conivaptan can be increased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Conivaptan can be increased when it is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Apraclonidine.Approved
ApremilastThe serum concentration of Conivaptan can be increased when it is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Conivaptan can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe serum concentration of Conivaptan can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Conivaptan can be increased when it is combined with Aripiprazole.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Conivaptan.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Conivaptan.Approved, Investigational
ArtemetherThe serum concentration of Conivaptan can be increased when it is combined with Artemether.Approved
AsenapineThe serum concentration of Conivaptan can be increased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Conivaptan can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Conivaptan can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Conivaptan can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Atenolol.Approved
AtomoxetineThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Conivaptan can be increased when it is combined with Avanafil.Approved
AxitinibThe serum concentration of Conivaptan can be increased when it is combined with Axitinib.Approved, Investigational
AzelastineThe serum concentration of Conivaptan can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe serum concentration of Conivaptan can be increased when it is combined with Azithromycin.Approved
BanoxantroneThe serum concentration of Conivaptan can be increased when it is combined with Banoxantrone.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Conivaptan.Experimental
BarbitalBarbital may increase the hypotensive activities of Conivaptan.Illicit
BaricitinibThe serum concentration of Conivaptan can be increased when it is combined with Baricitinib.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Conivaptan.Approved
BedaquilineThe serum concentration of Conivaptan can be increased when it is combined with Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Bendroflumethiazide.Approved
BenidipineThe serum concentration of Conivaptan can be increased when it is combined with Benidipine.Approved, Investigational
BenzphetamineThe serum concentration of Conivaptan can be increased when it is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe serum concentration of Conivaptan can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Conivaptan.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Betaxolol.Approved, Investigational
BexaroteneThe serum concentration of Conivaptan can be increased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe serum concentration of Conivaptan can be increased when it is combined with Bezafibrate.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Conivaptan.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Conivaptan can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Conivaptan can be increased when it is combined with Bictegravir.Approved, Investigational
BioallethrinThe serum concentration of Conivaptan can be increased when it is combined with Bioallethrin.Approved, Experimental
BisoprololThe serum concentration of Conivaptan can be increased when it is combined with Bisoprolol.Approved
BlonanserinThe serum concentration of Conivaptan can be increased when it is combined with Blonanserin.Approved, Investigational
BoceprevirThe serum concentration of Conivaptan can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Conivaptan can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Conivaptan can be increased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Conivaptan.Approved
Brentuximab vedotinThe serum concentration of Conivaptan can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Conivaptan is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Conivaptan can be increased when it is combined with Brexpiprazole.Approved, Investigational
BrigatinibThe serum concentration of Conivaptan can be increased when it is combined with Brigatinib.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Brimonidine.Approved
BrinzolamideThe serum concentration of Conivaptan can be increased when it is combined with Brinzolamide.Approved
BrivaracetamThe serum concentration of Conivaptan can be increased when it is combined with Brivaracetam.Approved, Investigational
BromazepamThe serum concentration of Conivaptan can be increased when it is combined with Bromazepam.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Conivaptan can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe serum concentration of Conivaptan can be increased when it is combined with Brompheniramine.Approved
BudesonideThe serum concentration of Conivaptan can be increased when it is combined with Budesonide.Approved
BumetanideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Conivaptan can be increased when it is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe serum concentration of Conivaptan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Conivaptan can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Conivaptan can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe serum concentration of Conivaptan can be increased when it is combined with Busulfan.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Conivaptan.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Conivaptan can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Conivaptan can be increased when it is combined with Cabergoline.Approved
CabozantinibThe serum concentration of Conivaptan can be increased when it is combined with Cabozantinib.Approved, Investigational
CaffeineThe serum concentration of Conivaptan can be increased when it is combined with Caffeine.Approved
CalcitriolThe serum concentration of Conivaptan can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CanagliflozinThe serum concentration of Conivaptan can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Conivaptan.Approved
CannabidiolThe serum concentration of Conivaptan can be increased when it is combined with Cannabidiol.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Captopril.Approved
CarbamazepineThe serum concentration of Conivaptan can be increased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Conivaptan.Approved, Investigational
CarbinoxamineThe serum concentration of Conivaptan can be increased when it is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Conivaptan.Illicit, Investigational, Vet Approved
CariprazineThe serum concentration of Conivaptan can be increased when it is combined with Cariprazine.Approved, Investigational
CarteololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Carteolol.Approved
CarvedilolThe serum concentration of Conivaptan can be increased when it is combined with Carvedilol.Approved, Investigational
CelecoxibThe serum concentration of Conivaptan can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Conivaptan can be increased when it is combined with Celiprolol.Approved, Investigational
CephalexinThe serum concentration of Conivaptan can be increased when it is combined with Cephalexin.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Conivaptan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Conivaptan can be increased when it is combined with Cerivastatin.Approved, Withdrawn
CevimelineThe serum concentration of Conivaptan can be increased when it is combined with Cevimeline.Approved
Chenodeoxycholic acidThe serum concentration of Conivaptan can be increased when it is combined with Chenodeoxycholic acid.Approved
ChlordiazepoxideThe serum concentration of Conivaptan can be increased when it is combined with Chlordiazepoxide.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Conivaptan can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Conivaptan can be increased when it is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Conivaptan can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Chlorthalidone.Approved
ChlorzoxazoneThe serum concentration of Conivaptan can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe serum concentration of Conivaptan can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe serum concentration of Conivaptan can be increased when it is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Conivaptan.Approved, Investigational
CilostazolThe serum concentration of Conivaptan can be increased when it is combined with Cilostazol.Approved, Investigational
CinacalcetThe serum concentration of Conivaptan can be increased when it is combined with Cinacalcet.Approved
CisaprideThe serum concentration of Conivaptan can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Conivaptan can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Conivaptan can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Conivaptan can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Clevidipine.Approved, Investigational
ClindamycinThe serum concentration of Conivaptan can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClobazamThe serum concentration of Conivaptan can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Conivaptan.Approved, Investigational
ClofazimineThe serum concentration of Conivaptan can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe serum concentration of Conivaptan can be increased when it is combined with Clofibrate.Approved, Investigational
clomethiazoleThe serum concentration of Conivaptan can be increased when it is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Conivaptan can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Conivaptan can be increased when it is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Conivaptan can be increased when it is combined with Clonidine.Approved
ClopidogrelThe serum concentration of Conivaptan can be increased when it is combined with Clopidogrel.Approved
ClorazepateThe serum concentration of Conivaptan can be increased when it is combined with Clorazepate.Approved, Illicit
ClotiazepamThe serum concentration of Conivaptan can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Conivaptan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Conivaptan can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Conivaptan can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Conivaptan.Approved, Investigational
CocaineThe serum concentration of Conivaptan can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe serum concentration of Conivaptan can be increased when it is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Conivaptan can be increased when it is combined with Colchicine.Approved
Conjugated estrogensThe serum concentration of Conivaptan can be increased when it is combined with Conjugated estrogens.Approved
CopanlisibThe serum concentration of Conivaptan can be increased when it is combined with Copanlisib.Approved, Investigational
Cortisone acetateThe serum concentration of Conivaptan can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe serum concentration of Conivaptan can be increased when it is combined with Crizotinib.Approved
CyclobenzaprineThe serum concentration of Conivaptan can be increased when it is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Conivaptan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Conivaptan can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Conivaptan can be increased when it is combined with Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Conivaptan can be increased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Conivaptan can be increased when it is combined with Daclatasvir.Approved, Investigational
DantroleneThe serum concentration of Conivaptan can be increased when it is combined with Dantrolene.Approved, Investigational
DapagliflozinThe serum concentration of Conivaptan can be increased when it is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Conivaptan.Investigational
DapsoneThe serum concentration of Conivaptan can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe serum concentration of Conivaptan can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Conivaptan can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Conivaptan can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Conivaptan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Conivaptan can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Conivaptan can be increased when it is combined with Deflazacort.Approved, Investigational
DelamanidThe serum concentration of Conivaptan can be increased when it is combined with Delamanid.Approved, Investigational
DelavirdineThe serum concentration of Conivaptan can be increased when it is combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Desflurane.Approved
DesvenlafaxineThe serum concentration of Conivaptan can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe serum concentration of Conivaptan can be increased when it is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Conivaptan can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Conivaptan can be increased when it is combined with Dexchlorpheniramine maleate.Approved
DexlansoprazoleThe serum concentration of Conivaptan can be increased when it is combined with Dexlansoprazole.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Conivaptan can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Conivaptan.Experimental, Illicit
DextropropoxypheneThe serum concentration of Conivaptan can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Conivaptan.Approved, Investigational
DiazepamThe serum concentration of Conivaptan can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Conivaptan can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Diclofenamide.Approved, Investigational
DienogestThe serum concentration of Conivaptan can be increased when it is combined with Dienogest.Approved
DigitoxinThe serum concentration of Conivaptan can be increased when it is combined with Digitoxin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Conivaptan.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Conivaptan can be increased when it is combined with Dihydro-alpha-ergocryptine.Approved
DihydrocodeineThe serum concentration of Conivaptan can be increased when it is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Conivaptan.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Conivaptan.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Conivaptan.Experimental
DihydroergotamineThe serum concentration of Conivaptan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Conivaptan.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.Experimental, Illicit
DiltiazemThe serum concentration of Conivaptan can be increased when it is combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Conivaptan is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Conivaptan.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Conivaptan is combined with Dipyridamole.Approved
DisopyramideThe serum concentration of Conivaptan can be increased when it is combined with Disopyramide.Approved
DisulfiramThe serum concentration of Conivaptan can be increased when it is combined with Disulfiram.Approved
DocetaxelThe serum concentration of Conivaptan can be increased when it is combined with Docetaxel.Approved, Investigational
DofetilideThe serum concentration of Conivaptan can be increased when it is combined with Dofetilide.Approved, Investigational
DolasetronThe serum concentration of Conivaptan can be increased when it is combined with Dolasetron.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Conivaptan can be increased when it is combined with Donepezil.Approved
DorzolamideThe serum concentration of Conivaptan can be increased when it is combined with Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Doxazosin.Approved
DoxepinThe serum concentration of Conivaptan can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Conivaptan can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Conivaptan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Conivaptan.Experimental
DronabinolThe serum concentration of Conivaptan can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Conivaptan can be increased when it is combined with Dronedarone.Approved
DuloxetineConivaptan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe serum concentration of Conivaptan can be increased when it is combined with Dutasteride.Approved, Investigational
EfavirenzThe serum concentration of Conivaptan can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Conivaptan can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Conivaptan can be increased when it is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Conivaptan can be increased when it is combined with Eliglustat.Approved
ElvitegravirThe serum concentration of Conivaptan can be increased when it is combined with Elvitegravir.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Conivaptan can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Conivaptan can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Conivaptan can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Conivaptan can be increased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Conivaptan can be increased when it is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Conivaptan is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Eprosartan.Approved
ErgocalciferolThe serum concentration of Conivaptan can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Conivaptan can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Conivaptan can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Conivaptan can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Conivaptan can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Conivaptan can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Conivaptan can be increased when it is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Esmolol.Approved
EsomeprazoleThe serum concentration of Conivaptan can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Conivaptan can be increased when it is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Conivaptan can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Conivaptan can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Conivaptan can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Conivaptan can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Conivaptan can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Conivaptan can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Conivaptan can be increased when it is combined with Estramustine.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Conivaptan can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Conivaptan can be increased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Conivaptan can be increased when it is combined with Estrone sulfate.Approved
EszopicloneThe serum concentration of Conivaptan can be increased when it is combined with Eszopiclone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Conivaptan is combined with Etacrynic acid.Approved, Investigational
EthanolThe serum concentration of Conivaptan can be increased when it is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Conivaptan can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe serum concentration of Conivaptan can be increased when it is combined with Ethosuximide.Approved
EthylmorphineThe serum concentration of Conivaptan can be increased when it is combined with Ethylmorphine.Approved, Illicit
EtizolamThe serum concentration of Conivaptan can be increased when it is combined with Etizolam.Approved
EtonogestrelThe serum concentration of Conivaptan can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Conivaptan can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Conivaptan can be increased when it is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Conivaptan.Illicit, Vet Approved
EtravirineThe serum concentration of Conivaptan can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Conivaptan can be increased when it is combined with Everolimus.Approved
ExemestaneThe serum concentration of Conivaptan can be increased when it is combined with Exemestane.Approved, Investigational
FamciclovirThe serum concentration of Conivaptan can be increased when it is combined with Famciclovir.Approved, Investigational
FelbamateThe serum concentration of Conivaptan can be increased when it is combined with Felbamate.Approved
FelodipineThe serum concentration of Conivaptan can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Conivaptan can be increased when it is combined with Fenofibrate.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fenoldopam.Approved
FentanylThe serum concentration of Conivaptan can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Conivaptan can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fimasartan.Approved, Investigational
FinasterideThe serum concentration of Conivaptan can be increased when it is combined with Finasteride.Approved
FingolimodThe serum concentration of Conivaptan can be increased when it is combined with Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Flibanserin.Approved, Investigational
FluconazoleThe metabolism of Conivaptan can be decreased when combined with Fluconazole.Approved, Investigational
FlunisolideThe serum concentration of Conivaptan can be increased when it is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe serum concentration of Conivaptan can be increased when it is combined with Flunitrazepam.Approved, Illicit
FluorometholoneThe serum concentration of Conivaptan can be increased when it is combined with Fluorometholone.Approved, Investigational
FluoxetineThe serum concentration of Conivaptan can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlurazepamThe serum concentration of Conivaptan can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlutamideThe serum concentration of Conivaptan can be increased when it is combined with Flutamide.Approved, Investigational
Fluticasone furoateThe serum concentration of Conivaptan can be increased when it is combined with Fluticasone furoate.Approved
Fluticasone propionateThe serum concentration of Conivaptan can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Conivaptan can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Conivaptan can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Conivaptan can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Conivaptan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fosinopril.Approved
FosnetupitantThe serum concentration of Conivaptan can be increased when it is combined with Fosnetupitant.Approved
FosphenytoinThe metabolism of Conivaptan can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Conivaptan can be increased when it is combined with Fostamatinib.Approved, Investigational
FulvestrantThe serum concentration of Conivaptan can be increased when it is combined with Fulvestrant.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Conivaptan can be increased when it is combined with Fusidic Acid.Approved, Investigational
GalantamineThe serum concentration of Conivaptan can be increased when it is combined with Galantamine.Approved
GefitinibThe serum concentration of Conivaptan can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Conivaptan can be increased when it is combined with Gemfibrozil.Approved
GlipizideThe serum concentration of Conivaptan can be increased when it is combined with Glipizide.Approved, Investigational
GlyburideThe serum concentration of Conivaptan can be increased when it is combined with Glyburide.Approved
GranisetronThe serum concentration of Conivaptan can be increased when it is combined with Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Conivaptan can be increased when it is combined with Grazoprevir.Approved
GrepafloxacinThe serum concentration of Conivaptan can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Conivaptan can be increased when it is combined with Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Conivaptan can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Conivaptan can be increased when it is combined with Haloperidol.Approved
HalothaneThe serum concentration of Conivaptan can be increased when it is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Conivaptan.Approved, Illicit, Investigational
HexobarbitalThe serum concentration of Conivaptan can be increased when it is combined with Hexobarbital.Approved
HistamineThe serum concentration of Conivaptan can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Conivaptan can be increased when it is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe serum concentration of Conivaptan can be increased when it is combined with Hydromorphone.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Conivaptan can be increased when it is combined with Hydroxyprogesterone caproate.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Conivaptan.Approved
IcotinibThe serum concentration of Conivaptan can be increased when it is combined with Icotinib.Approved, Investigational
IdelalisibThe serum concentration of Conivaptan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Conivaptan can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Conivaptan can be increased when it is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Conivaptan is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Conivaptan can be increased when it is combined with Imatinib.Approved
ImidafenacinThe serum concentration of Conivaptan can be increased when it is combined with Imidafenacin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Imidapril.Investigational
ImipramineThe serum concentration of Conivaptan can be increased when it is combined with Imipramine.Approved
ImiquimodThe serum concentration of Conivaptan can be increased when it is combined with Imiquimod.Approved, Investigational
IndacaterolThe serum concentration of Conivaptan can be increased when it is combined with Indacaterol.Approved
IndapamideThe serum concentration of Conivaptan can be increased when it is combined with Indapamide.Approved
IndinavirThe serum concentration of Conivaptan can be increased when it is combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Conivaptan is combined with Indoramin.Withdrawn
Ipratropium bromideThe serum concentration of Conivaptan can be increased when it is combined with Ipratropium bromide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Conivaptan can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Conivaptan can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Conivaptan can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Conivaptan can be increased when it is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Conivaptan can be increased when it is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Conivaptan can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Conivaptan can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Conivaptan.Approved
IvacaftorThe serum concentration of Conivaptan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Conivaptan can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Conivaptan can be increased when it is combined with Ixabepilone.Approved, Investigational
IxazomibThe serum concentration of Conivaptan can be increased when it is combined with Ixazomib.Approved, Investigational
KetamineThe serum concentration of Conivaptan can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Conivaptan can be increased when it is combined with Ketazolam.Approved
KetobemidoneThe serum concentration of Conivaptan can be increased when it is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Conivaptan can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Conivaptan is combined with Labetalol.Approved
LacidipineThe serum concentration of Conivaptan can be increased when it is combined with Lacidipine.Approved, Investigational
LansoprazoleThe serum concentration of Conivaptan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Conivaptan can be increased when it is combined with Lapatinib.Approved, Investigational
LaquinimodThe serum concentration of Conivaptan can be increased when it is combined with Laquinimod.Investigational
LenvatinibThe serum concentration of Conivaptan can be increased when it is combined with Lenvatinib.Approved, Investigational
LercanidipineThe serum concentration of Conivaptan can be increased when it is combined with Lercanidipine.Approved, Investigational
LetrozoleThe serum concentration of Conivaptan can be increased when it is combined with Letrozole.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Levobunolol.Approved
LevobupivacaineThe serum concentration of Conivaptan can be increased when it is combined with Levobupivacaine.Approved, Investigational
LevocetirizineThe serum concentration of Conivaptan can be increased when it is combined with Levocetirizine.Approved
LevodopaConivaptan may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe serum concentration of Conivaptan can be increased when it is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe serum concentration of Conivaptan can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe serum concentration of Conivaptan can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Conivaptan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Conivaptan can be increased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Conivaptan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lisinopril.Approved, Investigational
LisurideThe serum concentration of Conivaptan can be increased when it is combined with Lisuride.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Conivaptan.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Conivaptan.Approved, Investigational
LoperamideThe serum concentration of Conivaptan can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Conivaptan can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Conivaptan can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe serum concentration of Conivaptan can be increased when it is combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Conivaptan can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Conivaptan can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Conivaptan can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Conivaptan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Conivaptan can be increased when combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Conivaptan can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Conivaptan can be increased when it is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Conivaptan.Illicit, Investigational, Withdrawn
MacimorelinThe serum concentration of Conivaptan can be increased when it is combined with Macimorelin.Approved, Investigational
MacitentanThe serum concentration of Conivaptan can be increased when it is combined with Macitentan.Approved
MannitolThe risk or severity of adverse effects can be increased when Conivaptan is combined with Mannitol.Approved, Investigational
MaravirocThe serum concentration of Conivaptan can be increased when it is combined with Maraviroc.Approved, Investigational
MebendazoleThe serum concentration of Conivaptan can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Mecamylamine.Approved, Investigational
Medical CannabisThe serum concentration of Conivaptan can be increased when it is combined with Medical Cannabis.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Conivaptan can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Conivaptan can be increased when it is combined with Mefloquine.Approved, Investigational
MeloxicamThe serum concentration of Conivaptan can be increased when it is combined with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Conivaptan.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Conivaptan.Experimental
MethadoneThe serum concentration of Conivaptan can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Conivaptan.Approved, Illicit
MethaqualoneThe serum concentration of Conivaptan can be increased when it is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Conivaptan.Approved
MethoxsalenThe serum concentration of Conivaptan can be increased when it is combined with Methoxsalen.Approved
MethoxyfluraneThe serum concentration of Conivaptan can be increased when it is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Conivaptan is combined with Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Conivaptan.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Conivaptan.Approved
MethylprednisoloneThe serum concentration of Conivaptan can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Conivaptan can be increased when it is combined with Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Conivaptan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Conivaptan can be increased when it is combined with Metronidazole.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Conivaptan.Experimental
MexiletineThe serum concentration of Conivaptan can be increased when it is combined with Mexiletine.Approved, Investigational
MianserinThe serum concentration of Conivaptan can be increased when it is combined with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Conivaptan can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Conivaptan can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Conivaptan can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe serum concentration of Conivaptan can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Conivaptan can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Minoxidil.Approved, Investigational
MirabegronThe serum concentration of Conivaptan can be increased when it is combined with Mirabegron.Approved
MirtazapineThe serum concentration of Conivaptan can be increased when it is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Conivaptan can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Conivaptan can be increased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Moexipril.Approved
MontelukastThe serum concentration of Conivaptan can be increased when it is combined with Montelukast.Approved
MorphineThe serum concentration of Conivaptan can be increased when it is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Moxonidine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Conivaptan can be increased when it is combined with Mycophenolate mofetil.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nabilone.Approved, Investigational
NabiximolsThe serum concentration of Conivaptan can be increased when it is combined with Nabiximols.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Conivaptan.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Conivaptan.Approved
NaloxoneThe serum concentration of Conivaptan can be increased when it is combined with Naloxone.Approved, Vet Approved
NateglinideThe serum concentration of Conivaptan can be increased when it is combined with Nateglinide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Conivaptan can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Conivaptan can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Conivaptan can be increased when it is combined with Neratinib.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Conivaptan can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Conivaptan can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Conivaptan can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Conivaptan.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Conivaptan.Experimental
NicorandilNicorandil may increase the hypotensive activities of Conivaptan.Approved, Investigational
NicotineThe serum concentration of Conivaptan can be increased when it is combined with Nicotine.Approved
NifedipineThe serum concentration of Conivaptan can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Conivaptan can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Conivaptan can be increased when it is combined with Nilvadipine.Approved, Investigational
NimodipineThe serum concentration of Conivaptan can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Conivaptan can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Conivaptan can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Conivaptan can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitrous acid.Approved, Investigational
NorethisteroneThe serum concentration of Conivaptan can be increased when it is combined with Norethisterone.Approved
NorgestrelThe serum concentration of Conivaptan can be increased when it is combined with Norgestrel.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Conivaptan.Approved, Illicit
NortriptylineThe serum concentration of Conivaptan can be increased when it is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Conivaptan is combined with Obinutuzumab.Approved, Investigational
OdanacatibThe serum concentration of Conivaptan can be increased when it is combined with Odanacatib.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Conivaptan.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Olmesartan.Approved, Investigational
OlopatadineThe serum concentration of Conivaptan can be increased when it is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Conivaptan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Conivaptan can be increased when it is combined with Ondansetron.Approved
OpiumThe serum concentration of Conivaptan can be increased when it is combined with Opium.Approved, Illicit
OrphenadrineThe serum concentration of Conivaptan can be increased when it is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Conivaptan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Conivaptan can be increased when it is combined with Ospemifene.Approved, Investigational
OxazepamThe serum concentration of Conivaptan can be increased when it is combined with Oxazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Conivaptan can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe serum concentration of Conivaptan can be increased when it is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Conivaptan can be increased when it is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Conivaptan can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Conivaptan can be increased when it is combined with Palbociclib.Approved, Investigational
PalonosetronThe serum concentration of Conivaptan can be increased when it is combined with Palonosetron.Approved, Investigational
PanobinostatThe serum concentration of Conivaptan can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Conivaptan can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Papaverine.Approved, Investigational
ParamethadioneThe serum concentration of Conivaptan can be increased when it is combined with Paramethadione.Approved
ParamethasoneThe serum concentration of Conivaptan can be increased when it is combined with Paramethasone.Approved
ParecoxibThe serum concentration of Conivaptan can be increased when it is combined with Parecoxib.Approved
ParicalcitolThe serum concentration of Conivaptan can be increased when it is combined with Paricalcitol.Approved, Investigational
ParitaprevirThe serum concentration of Conivaptan can be increased when it is combined with Paritaprevir.Approved, Investigational
PazopanibThe serum concentration of Conivaptan can be increased when it is combined with Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Penbutolol.Approved, Investigational
PentamidineThe serum concentration of Conivaptan can be increased when it is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.Approved, Vet Approved
PentobarbitalThe metabolism of Conivaptan can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe serum concentration of Conivaptan can be increased when it is combined with Perampanel.Approved
PergolideThe serum concentration of Conivaptan can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Conivaptan can be increased when it is combined with Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Perindopril.Approved
PermethrinThe serum concentration of Conivaptan can be increased when it is combined with Permethrin.Approved, Investigational
PerospironeThe serum concentration of Conivaptan can be increased when it is combined with Perospirone.Approved
PerphenazineThe serum concentration of Conivaptan can be increased when it is combined with Perphenazine.Approved
PethidineThe serum concentration of Conivaptan can be increased when it is combined with Pethidine.Approved
PhenacetinThe serum concentration of Conivaptan can be increased when it is combined with Phenacetin.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Conivaptan.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Conivaptan can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Conivaptan.Experimental
PhenoxybenzamineThe serum concentration of Conivaptan can be increased when it is combined with Phenoxybenzamine.Approved
PhenprocoumonThe serum concentration of Conivaptan can be increased when it is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Conivaptan can be increased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Conivaptan can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe serum concentration of Conivaptan can be increased when it is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Conivaptan.Approved
PinacidilThe serum concentration of Conivaptan can be increased when it is combined with Pinacidil.Approved
PindololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pindolol.Approved, Investigational
PioglitazoneThe serum concentration of Conivaptan can be increased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Conivaptan can be increased when it is combined with Piperaquine.Approved, Investigational
PipotiazineThe serum concentration of Conivaptan can be increased when it is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Conivaptan.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Conivaptan.Approved
PitolisantThe serum concentration of Conivaptan can be increased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe serum concentration of Conivaptan can be increased when it is combined with Podofilox.Approved
PomalidomideThe serum concentration of Conivaptan can be increased when it is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Conivaptan can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Conivaptan can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pramipexole.Approved, Investigational
PrasteroneThe serum concentration of Conivaptan can be increased when it is combined with Prasterone.Approved, Investigational, Nutraceutical
PrasugrelThe serum concentration of Conivaptan can be increased when it is combined with Prasugrel.Approved
PravastatinThe serum concentration of Conivaptan can be increased when it is combined with Pravastatin.Approved
PrazepamThe serum concentration of Conivaptan can be increased when it is combined with Prazepam.Approved, Illicit
PraziquantelThe serum concentration of Conivaptan can be increased when it is combined with Praziquantel.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Conivaptan can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Conivaptan can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Conivaptan can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Conivaptan can be increased when combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Conivaptan can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Conivaptan can be increased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe serum concentration of Conivaptan can be increased when it is combined with Proguanil.Approved
PromazineThe serum concentration of Conivaptan can be increased when it is combined with Promazine.Approved, Vet Approved
PropafenoneThe serum concentration of Conivaptan can be increased when it is combined with Propafenone.Approved
PropiverineThe serum concentration of Conivaptan can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe serum concentration of Conivaptan can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Conivaptan can be increased when it is combined with Propoxyphene napsylate.Approved
PropranololThe serum concentration of Conivaptan can be increased when it is combined with Propranolol.Approved, Investigational
PyrazinamideThe serum concentration of Conivaptan can be increased when it is combined with Pyrazinamide.Approved, Investigational
QuazepamThe serum concentration of Conivaptan can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Conivaptan can be increased when it is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Conivaptan can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Conivaptan can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Conivaptan can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Conivaptan can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Conivaptan can be increased when it is combined with Raloxifene.Approved, Investigational
RamelteonThe serum concentration of Conivaptan can be increased when it is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Ramipril.Approved
RanolazineThe serum concentration of Conivaptan can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Conivaptan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Conivaptan can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.Approved
RepaglinideThe serum concentration of Conivaptan can be increased when it is combined with Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Reserpine.Approved, Investigational
RetapamulinThe serum concentration of Conivaptan can be increased when it is combined with Retapamulin.Approved
RibociclibThe serum concentration of Conivaptan can be increased when it is combined with Ribociclib.Approved, Investigational
RifabutinThe serum concentration of Conivaptan can be increased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Conivaptan can be increased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Conivaptan can be increased when combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Conivaptan can be increased when it is combined with Rilpivirine.Approved
RimonabantThe serum concentration of Conivaptan can be increased when it is combined with Rimonabant.Approved, Investigational
RiociguatThe serum concentration of Conivaptan can be increased when it is combined with Riociguat.Approved
RisperidoneThe serum concentration of Conivaptan can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Conivaptan can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Conivaptan can be increased when it is combined with Rivaroxaban.Approved
RofecoxibThe serum concentration of Conivaptan can be increased when it is combined with Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Conivaptan can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Conivaptan can be increased when it is combined with Romidepsin.Approved, Investigational
RopiniroleThe serum concentration of Conivaptan can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Conivaptan can be increased when it is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Conivaptan can be increased when it is combined with Rosuvastatin.Approved
RotigotineThe serum concentration of Conivaptan can be increased when it is combined with Rotigotine.Approved
RoxithromycinThe serum concentration of Conivaptan can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Conivaptan can be increased when it is combined with Rucaparib.Approved, Investigational
RupatadineThe serum concentration of Conivaptan can be increased when it is combined with Rupatadine.Approved
RuxolitinibThe serum concentration of Conivaptan can be increased when it is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Sacubitril.Approved
SafinamideThe serum concentration of Conivaptan can be increased when it is combined with Safinamide.Approved, Investigational
SalmeterolThe serum concentration of Conivaptan can be increased when it is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Conivaptan can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Conivaptan can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Conivaptan can be increased when it is combined with Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
SelegilineThe serum concentration of Conivaptan can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Conivaptan can be increased when it is combined with Selexipag.Approved
SeratrodastThe serum concentration of Conivaptan can be increased when it is combined with Seratrodast.Approved
SertindoleThe serum concentration of Conivaptan can be increased when it is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Conivaptan can be increased when it is combined with Sertraline.Approved
SevofluraneThe serum concentration of Conivaptan can be increased when it is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe serum concentration of Conivaptan can be increased when it is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Conivaptan can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Conivaptan can be increased when it is combined with Silodosin.Approved
SiltuximabThe serum concentration of Conivaptan can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Conivaptan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Conivaptan can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Conivaptan can be increased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Conivaptan can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium phosphateConivaptan may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Conivaptan can be increased when it is combined with Solifenacin.Approved
SonidegibThe serum concentration of Conivaptan can be increased when it is combined with Sonidegib.Approved, Investigational
SorafenibThe serum concentration of Conivaptan can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Conivaptan is combined with Sotalol.Approved
SpiramycinThe serum concentration of Conivaptan can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Conivaptan can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Conivaptan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Conivaptan is combined with Streptokinase.Approved, Investigational
SufentanilThe serum concentration of Conivaptan can be increased when it is combined with Sufentanil.Approved, Investigational
SulfadiazineThe serum concentration of Conivaptan can be increased when it is combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Conivaptan can be increased when it is combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Conivaptan can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Conivaptan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Conivaptan can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Conivaptan.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Conivaptan can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Conivaptan can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrolimusThe serum concentration of Conivaptan can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Conivaptan can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Conivaptan can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe serum concentration of Conivaptan can be increased when it is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Conivaptan.Approved
TasosartanThe serum concentration of Conivaptan can be increased when it is combined with Tasosartan.Approved
Taurochenodeoxycholic acidThe serum concentration of Conivaptan can be increased when it is combined with Taurochenodeoxycholic acid.Experimental
TelaprevirThe serum concentration of Conivaptan can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Conivaptan can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Telmisartan.Approved, Investigational
TemazepamThe serum concentration of Conivaptan can be increased when it is combined with Temazepam.Approved, Investigational
TemsirolimusThe serum concentration of Conivaptan can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Conivaptan can be increased when it is combined with Teniposide.Approved
TerazosinThe risk or severity of adverse effects can be increased when Conivaptan is combined with Terazosin.Approved
TerbinafineThe serum concentration of Conivaptan can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Conivaptan can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Conivaptan.Experimental
TesmilifeneThe serum concentration of Conivaptan can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Conivaptan can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Conivaptan can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Conivaptan can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Conivaptan can be increased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Conivaptan can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Conivaptan can be increased when it is combined with Tetracycline.Approved, Vet Approved
TezacaftorThe serum concentration of Conivaptan can be increased when it is combined with Tezacaftor.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Conivaptan can be increased when it is combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thioridazine.Approved, Withdrawn
ThiotepaThe serum concentration of Conivaptan can be increased when it is combined with Thiotepa.Approved, Investigational
TiagabineThe serum concentration of Conivaptan can be increased when it is combined with Tiagabine.Approved, Investigational
TicagrelorThe serum concentration of Conivaptan can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Conivaptan can be increased when it is combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Conivaptan.Experimental
TimololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Timolol.Approved
TinidazoleThe serum concentration of Conivaptan can be increased when it is combined with Tinidazole.Approved, Investigational
TiotropiumThe serum concentration of Conivaptan can be increased when it is combined with Tiotropium.Approved
TipranavirThe serum concentration of Conivaptan can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Conivaptan can be increased when it is combined with Tocofersolan.Approved
TocopherolThe serum concentration of Conivaptan can be increased when it is combined with Tocopherol.Approved, Investigational
TofacitinibThe serum concentration of Conivaptan can be increased when it is combined with Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolcapone.Approved, Withdrawn
TolterodineThe serum concentration of Conivaptan can be increased when it is combined with Tolterodine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Conivaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Torasemide.Approved
ToremifeneThe serum concentration of Conivaptan can be increased when it is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Conivaptan can be increased when it is combined with Trabectedin.Approved, Investigational
TramadolThe serum concentration of Conivaptan can be increased when it is combined with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Conivaptan can be increased when it is combined with Trastuzumab emtansine.Approved, Investigational
TrazodoneThe serum concentration of Conivaptan can be increased when it is combined with Trazodone.Approved, Investigational
TretinoinThe serum concentration of Conivaptan can be increased when it is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Conivaptan can be increased when it is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Triamterene.Approved
TriazolamThe serum concentration of Conivaptan can be increased when it is combined with Triazolam.Approved, Investigational
TrimethadioneThe serum concentration of Conivaptan can be increased when it is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Conivaptan can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Conivaptan can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe serum concentration of Conivaptan can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Conivaptan can be increased when it is combined with Troleandomycin.Approved
UdenafilThe serum concentration of Conivaptan can be increased when it is combined with Udenafil.Approved, Investigational
UlipristalThe serum concentration of Conivaptan can be increased when it is combined with Ulipristal.Approved
ValbenazineThe serum concentration of Conivaptan can be increased when it is combined with Valbenazine.Approved, Investigational
ValdecoxibThe serum concentration of Conivaptan can be increased when it is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Valsartan.Approved, Investigational
VandetanibThe serum concentration of Conivaptan can be increased when it is combined with Vandetanib.Approved
VanoxerineThe serum concentration of Conivaptan can be increased when it is combined with Vanoxerine.Investigational
VardenafilThe serum concentration of Conivaptan can be increased when it is combined with Vardenafil.Approved
VelpatasvirThe serum concentration of Conivaptan can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Conivaptan can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Conivaptan can be increased when it is combined with Venetoclax.Approved, Investigational
VenlafaxineThe serum concentration of Conivaptan can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Conivaptan can be increased when it is combined with Verapamil.Approved
VicrivirocThe serum concentration of Conivaptan can be increased when it is combined with Vicriviroc.Investigational
VilanterolThe serum concentration of Conivaptan can be increased when it is combined with Vilanterol.Approved
VilazodoneThe serum concentration of Conivaptan can be increased when it is combined with Vilazodone.Approved
VinblastineThe serum concentration of Conivaptan can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Conivaptan can be increased when it is combined with Vincristine.Approved, Investigational
VindesineThe serum concentration of Conivaptan can be increased when it is combined with Vindesine.Approved, Investigational
VinflunineThe serum concentration of Conivaptan can be increased when it is combined with Vinflunine.Approved, Investigational
VinorelbineThe serum concentration of Conivaptan can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Conivaptan can be increased when it is combined with Vismodegib.Approved, Investigational
VoriconazoleThe serum concentration of Conivaptan can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Conivaptan can be increased when it is combined with Vortioxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Conivaptan can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinThe serum concentration of Conivaptan can be increased when it is combined with Warfarin.Approved
YohimbineThe serum concentration of Conivaptan can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Conivaptan can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe serum concentration of Conivaptan can be increased when it is combined with Zalcitabine.Approved, Investigational
ZaleplonThe serum concentration of Conivaptan can be increased when it is combined with Zaleplon.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Conivaptan can be increased when it is combined with Zidovudine.Approved
ZileutonThe serum concentration of Conivaptan can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Conivaptan can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Conivaptan can be increased when it is combined with Zolpidem.Approved
ZomepiracThe serum concentration of Conivaptan can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Conivaptan can be increased when it is combined with Zonisamide.Approved, Investigational
ZopicloneThe serum concentration of Conivaptan can be increased when it is combined with Zopiclone.Approved
ZotepineThe serum concentration of Conivaptan can be increased when it is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259]
  2. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403]
  3. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444]
External Links
Human Metabolome Database
HMDB0015010
KEGG Drug
D01236
PubChem Compound
151171
PubChem Substance
46504533
ChemSpider
133239
BindingDB
85095
ChEBI
681850
ChEMBL
CHEMBL1755
Therapeutic Targets Database
DNC001525
PharmGKB
PA164742939
IUPHAR
2203
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Conivaptan
ATC Codes
C03XA02 — Conivaptan
FDA label
Download (145 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHyponatremias / Kidney Diseases1
1CompletedNot AvailableHyponatremias / Liver Diseases1
1CompletedNot AvailableLiver Diseases1
1CompletedTreatmentSevere Traumatic Brain Injury1
2CompletedTreatmentChronic Heart Failure (CHF)1
2CompletedTreatmentLiver Cirrhosis1
2WithdrawnTreatmentAcute Cerebrovascular Accidents / Edema of the cerebrum1
3CompletedTreatmentHyponatremias2
3TerminatedTreatmentAcute Decompensated Heart Failure (ADHF) / Hyponatremias1
3TerminatedTreatmentHyponatremias1
3WithdrawnTreatmentHyponatremias1
4CompletedTreatmentEuvolemia / Hyponatremias / Volume Overload1
4CompletedTreatmentHeart Failure, Unspecified1
4TerminatedTreatmentHyponatremias1
4WithdrawnTreatmentHeart Failure, Unspecified1
Not AvailableEnrolling by InvitationTreatmentEdema of the cerebrum / Intracerebral Hemorrhage / Strokes1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableWithdrawnTreatmentPulmonary Hypertension (PH) / Right Heart Failure1

Pharmacoeconomics

Manufacturers
  • Astellas pharma us inc
Packagers
  • Astellas Pharma Inc.
  • Baxter International Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntravenous20 mg/100mL
Prices
Unit descriptionCostUnit
Vaprisol 20 mg/100 ml bag6.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5723606No1999-12-152019-12-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble (0.15 mg/mL at 23 °C)Not Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00175 mg/mLALOGPS
logP5.23ALOGPS
logP5.44ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)11.14ChemAxon
pKa (Strongest Basic)6.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.09 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity150.83 m3·mol-1ChemAxon
Polarizability55.51 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9522
Caco-2 permeable+0.5291
P-glycoprotein substrateSubstrate0.5919
P-glycoprotein inhibitor IInhibitor0.6901
P-glycoprotein inhibitor IIInhibitor0.8429
Renal organic cation transporterNon-inhibitor0.6631
CYP450 2C9 substrateNon-substrate0.7671
CYP450 2D6 substrateNon-substrate0.7534
CYP450 3A4 substrateSubstrate0.6602
CYP450 1A2 substrateInhibitor0.7008
CYP450 2C9 inhibitorInhibitor0.5368
CYP450 2D6 inhibitorNon-inhibitor0.6597
CYP450 2C19 inhibitorInhibitor0.8477
CYP450 3A4 inhibitorInhibitor0.9027
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9043
Ames testNon AMES toxic0.6672
CarcinogenicityNon-carcinogens0.8831
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.5446 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Inhibitor0.8456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Biphenyls and derivatives / Benzazepines / Benzamides / Benzoyl derivatives / Azepines / Tertiary carboxylic acid amides / Imidazoles / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 5 more
Substituents
Benzanilide / Biphenyl / Benzazepine / Benzamide / Benzoic acid or derivatives / Benzoyl / Azepine / Azole / Heteroaromatic compound / Imidazole
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzazepine (CHEBI:681850)

Targets

Details
1. Vasopressin V1a receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
Gene Name
AVPR1A
Uniprot ID
P37288
Uniprot Name
Vasopressin V1a receptor
Molecular Weight
46799.105 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259]
  3. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666]
  4. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003]
  5. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403]
  6. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696]
  7. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376]
  8. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444]
  9. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103]
  10. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609]
Details
2. Vasopressin V2 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name
AVPR2
Uniprot ID
P30518
Uniprot Name
Vasopressin V2 receptor
Molecular Weight
40278.57 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M, Miyata K: Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51. Epub 2005 Jan 1. [PubMed:15659304]
  3. Palm C, Pistrosch F, Herbrig K, Gross P: Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006 Jul;119(7 Suppl 1):S87-92. [PubMed:16843091]
  4. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259]
  5. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666]
  6. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003]
  7. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403]
  8. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696]
  9. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376]
  10. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444]
  11. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103]
  12. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259]

Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:19